GLP-1s and Hair Loss: What’s Actually Happening, and What You Can Do
October 9, 2026
Featuring: Dr. Kay Durairaj
GLP-1 medications such as semaglutide and tirzepatide have been associated with increased hair shedding, particularly during rapid weight loss. Research suggests this is often telogen effluvium, triggered by factors such as reduced calorie and protein intake, nutritional deficiencies and physiological stress. In some people, weight loss may also reveal underlying androgenetic alopecia. Understanding the cause is key to supporting healthier hair growth.
GLP-1 Hair Loss is Becoming More Common
If you’ve started semaglutide (Ozempic®, Wegovy®) or tirzepatide (Mounjaro®, Zepbound®) and noticed more hair in your brush, you’re not alone.
Hair loss isn’t an official listed side effect of every GLP-1 medication, but research is catching up to what patients and clinicians have been observing. And according to facial plastic surgeon and hair restoration expert Dr. Kay Durairaj of Beauty By Dr. Kay it has become an increasingly common concern among patients using GLP-1 medications.
“I have seen so much GLP-1-mediated hair loss, and patients are dropping the use of their GLP because of hair thinning,” Dr. Durairaj explains.
Understanding why shedding may occur is important because the medication itself may not be the whole story and there are things you can do to help prevent it from happening in the first place.
What the Research Shows
A 2026 systematic review in Skin Research and Technology (Gupta et al.) analyzed 24 studies and found GLP-1 receptor agonists, especially semaglutide and tirzepatide, are linked to non-scarring hair loss, mostly telogen effluvium and, in some cases, the unmasking of underlying androgenetic alopecia (AGA).
The effect was dose-dependent, more pronounced with greater weight loss, and disproportionately reported by women. A University of Pennsylvania study reported that GLP-1 patients were 37% more likely to be diagnosed with hair loss than SGLT-2 inhibitor users and 68% more likely than DPP-4 inhibitor users. Zepbound® trial data reported hair loss in 7.1% of female patients compared with 1.3% receiving placebo.
A newer cross-sectional study published in Skin Appendage Disorders (Alharbi and Alkhalifah, 2026) found an even stronger signal in real-world use. Among 152 users with no prior hair loss, 70.4% reported shedding after beginning treatment, approximately ten times the 3% to 7% rates reported in registration trials.
Among patients who lost 15% or more of their body weight, reported shedding increased to 82.7%.
Importantly, the magnitude of weight loss, rather than the specific drug used, was the strongest predictor. The apparent association with tirzepatide disappeared after researchers accounted for the amount of weight lost.
Because this was a self-reported survey rather than a randomized clinical trial, the exact percentages should be viewed as directional rather than definitive.
Why Can Hair Loss Happen With GLP-1s?
One of the leading explanations isn’t necessarily the medication acting directly on the hair follicle. Instead, rapid weight loss, reduced caloric intake and changes in nutrition may create physiological stress that affects the normal hair-growth cycle.
Dr. Kay sees this frequently in her own patients.
“Appetites are gone, and people just are forcing themselves to eat. The protein intake has dropped drastically, and hair requires protein, it requires iron, and it requires vitamin D to grow,” she explains. “These are the top three things that I’m seeing deficiencies in with our GLP patients, and these things really drastically impact hair growth.”
Rapid weight loss and nutritional changes can contribute to telogen effluvium, a form of diffuse shedding that occurs when physiological stress causes a larger-than-normal number of follicles to transition into the resting phase of the hair cycle.
She adds:
“GLP-1, in a way, is a form of nutritional stress, and that really accelerates what they’ve already been going through.”
GLP-1s May Not Be the Only Factor
Not every patient who experiences shedding while taking a GLP-1 medication has the same underlying cause. For some patients, rapid weight loss or nutritional changes may trigger temporary telogen effluvium. For others, that stress may expose or accelerate an underlying tendency toward androgenetic alopecia. Hair loss is often multifactorial.
Hormonal changes, menopause or perimenopause, postpartum changes, stress, nutritional deficiencies and genetic hair loss may already be affecting the follicle before GLP-1 therapy begins. This means simply assuming that “the GLP-1 is causing my hair loss” may overlook other contributing factors.
Dr. Kay emphasizes the importance of looking deeper, particularly at nutritional status and iron stores.
“You just cannot grow hair when you have no iron stores,” she explains. “I think doing a full screening, biomarker testing, blood level testing is really critical.”
What Can You Do About GLP-1-Associated Hair Loss?
The first step is understanding what type of hair loss you’re actually experiencing.
Talk with the healthcare provider prescribing your GLP-1 medication and consider consulting a dermatologist or hair-loss specialist rather than stopping treatment or attempting to treat the shedding on your own.
Depending on the individual, evaluation may include nutritional intake, iron or ferritin status, vitamin levels, hormonal factors and signs of underlying androgenetic alopecia. Adequate protein and nutrient intake may also be particularly important during periods of significant weight loss.
And if GLP-1-associated shedding has uncovered an underlying hair-loss condition, addressing that condition may require a different strategy than simply waiting for telogen effluvium to resolve.
Where Does Revian Fit?
Revian has not conducted a clinical trial specifically in patients experiencing GLP-1-associated hair loss, and photobiomodulation is not a treatment for nutritional deficiencies.
Revian RED is cleared for the treatment of androgenetic alopecia and uses a patented combination of 620 nm and 660 nm LED light designed to address multiple biological pathways associated with hair growth.
The dual-wavelength approach supports follicular activity through mechanisms associated with mitochondrial activity and cellular energy, blood flow, inflammation and DHT-related pathways. Learn How it Works.
If shedding is primarily being driven by rapid weight loss or a nutritional deficiency, identifying and addressing those underlying factors is important. But when that period of physiological stress unmasks or occurs alongside androgenetic alopecia, a hair-growth treatment targeting the follicle may become part of a broader strategy. Hair loss rarely has only one contributing factor, which is why understanding the cause matters before deciding how to treat it.
The Bottom Line
GLP-1-associated hair shedding is increasingly being reported both in research and in clinical practice. Current evidence suggests that the amount and speed of weight loss, changes in nutrition and the resulting physiological stress may be important contributors. For some people, this may lead to temporary telogen effluvium. For others, it may reveal an underlying predisposition to androgenetic alopecia.
The encouraging part is that experiencing shedding doesn’t necessarily mean the hair loss is permanent or that GLP-1 treatment needs to be abandoned. Instead, it is a reason to look more closely at what is happening.
As Dr. Kay’s clinical experience highlights, evaluating nutrition, protein intake, iron stores and other potential contributors can be an important part of that process. And when underlying androgenetic alopecia is present, treatments specifically designed to support hair growth may also have a role.
Talk with your healthcare provider before assuming shedding is permanent, stopping a prescribed medication or beginning a hair-loss treatment.
This article is not intended to be medical advice. If you’re experiencing hair loss while taking a GLP-1 medication, consult your prescribing healthcare provider or a dermatologist.
Frequently Asked Questions
Can GLP-1s cause hair loss?
Increased shedding has been reported with GLP-1 use, particularly with significant or rapid weight loss.
Why does it happen?
Rapid weight loss, reduced calorie and protein intake, nutritional changes and physiological stress may contribute.
Is GLP-1 hair loss permanent?
Telogen effluvium is generally temporary, but underlying androgenetic alopecia may require treatment.
Should you stop your GLP-1?
Do not stop a prescribed medication because of shedding without discussing it with your healthcare provider.
Can Revian help?
Revian is not a treatment for nutritional deficiency or specifically for GLP-1-associated shedding. Revian RED is cleared for androgenetic alopecia, which may coexist with or become more apparent during GLP-1-associated shedding.
Sources:
- Dr. Kay Durairaj and Dr. Jordan R. Plews. REVIAN educational webinar: “The Science of Dual-Wavelength Photobiomodulation.” Watch the Webinar.
- REVIAN. Dual-wavelength LED Therapy & DHT Inhibition: research summary and supporting data. View source
- Kocher J, et al. “Dual Wavelength LEDs Induce Reactive Oxygen Species and Nitric Oxide That Inhibit the Production of Dihydrotestosterone by 5-α Reductase.” Journal of Biophotonics (2025). View source
- U.S. FDA. Zepbound® (tirzepatide) Prescribing Information: hair loss data from pooled Studies 1 and 2. View source
- Penn Medicine. “Diabetic GLP-1 use linked to increased hair loss risk” (2026), summarizing the University of Pennsylvania cohort published in The BMJ. View source
- Alharbi S, Alkhalifah A. “Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.” Skin Appendage Disorders (2026). View source
- Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. “GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.” Science Progress (2026). View source
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Revian is not affiliated with, sponsored by, or endorsed by either company; these marks are referenced solely to identify the medications discussed.
